Dr Omid Hamid on Choosing Targeted Therapy in Advanced Melanoma

Source: AJMC, June 2022

Omid A. Hamid, MD, spoke with The American Journal of Managed Care® (AJMC®) about evaluating patients with advanced melanoma for targeted treatment options, including understanding toxicity risks, deciding who would be candidates for immune checkpoint inhibitors, what to do when immunotherapy cannot be tolerated, and more.

He is the chief of Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute.

AJMC®: Risk of toxicity is a major consideration for patients with resected stage III melanoma. How do you evaluate if the patient should receive adjuvant therapy?

READ THE ORIGINAL FULL ARTICLE